Scalper1 News
Biotech Sarepta Therapeutics’ (SRPT) stock price was cut in half Friday after the FDA released highly critical briefing documents for an advisory committee evaluating Sarepta’s muscular dystrophy drug. The committee is scheduled to meet next Friday to review eteplirsen, a drug for Duchenne muscular dystrophy (DMD). Sarepta filed for approval of the drug last year after a long back-and-forth with the FDA over the appropriate amount of evidence in Scalper1 News
Scalper1 News